Contribution Of Broad Spectrum Dengue Diagnostic Technology In The Effort To Fight Dengue Global Disease Burden | 99970
Journal of Infectious Diseases & Therapy
Our Group organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.
The increasing burden of dengue virus infection continues to impact populations across the globe, highlighting the importance
of multi-parameter dengue diagnostic technologies. Market and literature reviews show that since 2016, there is a soaring
demand for early diagnosis of dengue infection, disease discrimination from other flaviviruses such as Zika, and development
of accurate serological standards. As a point-of-care IVD company developing and manufacturing dengue antigens, antibodies,
and IVD assays for the past decade, CTK Biotech has first-handedly witnessed the extreme limitations in undersourced and
remote areas. Thus, as a company, CTK aims to address the issues of quality, ease-of-use, and pricing in an array of dengue
products. For early detection of actively replicating virus, CTK offers a real-time PCR test that distinguishes between dengue
and related viruses Zika and Chikungunya, and a serotyping assay that identifies dengue types 1-4. For qualification of dengue
infection status, they have developed an IgM/IgG antibody test that determines an early or late stage active infection, and an
IgG antibody test that identifies past infection only. These products were clinically evaluated in endemic regions, which include
Brazil, Venezuela, Colombia, Peru, Mexico, Malaysia, India, and Bangladesh. Because serological standardization and controls
for dengue diagnostics remain a challenge, CTK has developed recombinant dengue murine-human chimeric IgM and IgG
antibodies, and are currently developing a quantification method using WHO standards for IgG and IgM. As each technology
has its advantages, CTK is committed to the fight against dengue infection and aims to contribute from every angle.
Ryen MacDonald completed her PhD in Neurosciences from McGill University and works as a Product Manager for CTK Biotech Inc, Inc located in San Diego, California.